HCPCS code J2998: Plasminogen injection, per 1 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J2998 covers

J2998 identifies human plasminogen-tvmh, a replacement product for patients with type 1 congenital plasminogen deficiency. The deficiency can cause abnormal lesions on mucous membranes, including the eyes. Treatment is administered by intravenous infusion under a clinician's direction. This product replaces deficient plasminogen; it is not a thrombolytic for acute clot management.

The HCPCS unit represents 1 mg, so report the total milligrams administered as the corresponding number of units. J2998 has physician fee schedule status E and is excluded from the physician fee schedule. When Medicare covers the drug, payment is made under another payment method; CMS identifies it as a Part B drug generally priced using quarterly ASP files. Coverage is left to the Medicare contractor's judgment. The drug code identifies the product quantity; CPT 96365 may identify the initial therapeutic infusion administration when applicable.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J2998 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J2998 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J2998 rate is calculated

Each of J2998’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J2998

J2998 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J2998 compared with similar codes

How to choose

J2997Alteplase injectionPer 1 mg

J2997 identifies alteplase, a thrombolytic drug. J2998 identifies human plasminogen-tvmh replacement therapy for congenital plasminogen deficiency.

J2993Reteplase injectionPer 18.1 mg

J2993 identifies reteplase, a thrombolytic drug; J2998 identifies human plasminogen-tvmh used for congenital plasminogen deficiency.

Codes related to J2998

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates